Lung Cancer

Lower Dose of Afatinib Shows Promising Clinical Efficacy in Patients with NSCLC and EGFR Mutation

2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021

Patients treated with afatinib for EGFR-mutated (EGFRm) non–small-cell lung cancer (NSCLC) often require treatment modifications because of drug toxicities. This study aimed to evaluate the safety and efficacy of a lower dosage of afatinib in patients with EGFRm NSCLC.

Tepotinib in NSCLC with MET Exon 14 Skipping Mutation (VISION Study)

2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021

The open-label, phase 2 VISION study evaluated the efficacy and safety of tepotinib, a highly selective oral MET inhibitor, in patients with advanced NSCLC with MET alterations.

ADAURA Trial: Osimertinib in Resected EGFR-Mutated NSCLC

2020 Year in Review: Non–Small-Cell Lung Cancer | February 6, 2021

Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC.

The Role of Rearrangement During Transfection (RET) Fusions as Oncogenic Drivers

Web Exclusives | December 21, 2020

Molecular Profiling Plays a Key Role in Optimizing NSCLC Therapy

Web Exclusives | December 21, 2020

Combination Cyramza and Tarceva Approved for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

Web Exclusives | December 21, 2020

Combination Opdivo plus Yervoy with Chemotherapy Approved as First-Line Treatment for Metastatic NSCLC

Web Exclusives | December 21, 2020

New Drug Application for the RET Kinase Inhibitor Selpercatinib Receives Priority Review